These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Establishing guidance for the handling and containment of new chemical entities and chemical intermediates in the pharmaceutical industry. Olson MJ; Binks SP; Newton DL; Clark GC Occup Med; 1997; 12(1):49-65. PubMed ID: 9153052 [TBL] [Abstract][Full Text] [Related]
5. Legal issues associated with the handling of cytotoxic drugs. Provost GJ Am J Hosp Pharm; 1984 Jun; 41(6):1115-21. PubMed ID: 6234797 [TBL] [Abstract][Full Text] [Related]
7. Manufacturers' recommendations for handling spilled hazardous drugs. Gonzalez R; Massoomi FF Am J Health Syst Pharm; 2010 Dec; 67(23):1985-6. PubMed ID: 21098367 [No Abstract] [Full Text] [Related]
8. Need for specific data on incineration of antineoplastic agents. Habeger HE Am J Hosp Pharm; 1983 Sep; 40(9):1468. PubMed ID: 6624746 [No Abstract] [Full Text] [Related]
9. Pharmacy program for improved handling of antineoplastic agents. Scott SA; Schrott DB; Loesch GA Am J Hosp Pharm; 1983 Jul; 40(7):1179-82. PubMed ID: 6881156 [TBL] [Abstract][Full Text] [Related]
10. Antineoplastic admixture service in a tertiary-care hospital. Friedman TS; Triboletti M; Sandusky RM; Katz S Am J Hosp Pharm; 1984 Oct; 41(10):2037-44. PubMed ID: 6496492 [TBL] [Abstract][Full Text] [Related]
11. Safe disposal of some commonly used injectable antineoplastic drugs. Wilson SJ J Clin Hosp Pharm; 1983 Sep; 8(3):295-9. PubMed ID: 6630568 [TBL] [Abstract][Full Text] [Related]
12. Pharmacist participation in the management of incidents involving hazardous materials. Levy DB; Barone JA; Raia JJ; York JM; Vogel DP Am J Hosp Pharm; 1987 Mar; 44(3):549-56. PubMed ID: 3551595 [TBL] [Abstract][Full Text] [Related]
13. Hospital-based training for pharmaceutical manufacturers' representatives. Powell SH; Stempien MJ; Vogenberg FR Am J Hosp Pharm; 1984 Jan; 41(1):70, 74. PubMed ID: 6695935 [No Abstract] [Full Text] [Related]
14. Handling of gene-transfer products by the National Institutes of Health Clinical Center pharmacy department. DeCederfelt HJ; Grimes GJ; Green L; DeCederfelt RO; Daniels CE Am J Health Syst Pharm; 1997 Jul; 54(14):1604-10. PubMed ID: 9248603 [TBL] [Abstract][Full Text] [Related]
15. Rethinking pharmaceutical industry relationships. Crane VS; Jefferson KK; Morgan R Am J Hosp Pharm; 1987 Aug; 44(8):1884-6. PubMed ID: 3631111 [No Abstract] [Full Text] [Related]
16. Recommendations for the safe handling of injectable antineoplastic drug products. Zimmerman PF; Larsen RK; Barkley EW; Gallelli JF Am J Hosp Pharm; 1981 Nov; 38(11):1693-5. PubMed ID: 7304621 [TBL] [Abstract][Full Text] [Related]
17. Biosafety in acquired immunodeficiency syndrome (AIDS) studies using nonhuman primates. Broderson JR J Med Primatol; 1987; 16(2):131-8. PubMed ID: 3035186 [TBL] [Abstract][Full Text] [Related]
19. Replies to the question: should the practice of drug sampling be retained or eliminated? Hosp Formul; 1994 Oct; 29(10):720-2. PubMed ID: 10137849 [No Abstract] [Full Text] [Related]
20. Chemotherapy exposure file. Young RL; Du Vall EM Am J Hosp Pharm; 1985 Sep; 42(9):1990-1. PubMed ID: 3840330 [No Abstract] [Full Text] [Related] [Next] [New Search]